Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia

The Pharmacogenomics Journal
M KrajinovicG Andelfinger

Abstract

Anthracyclines are efficient chemotherapy agents. However, their use is limited by anthracycline-induced cardiotoxicity (CT). We investigated the influence of polymorphisms in doxorubicin metabolic and functional pathways on late-onset CT as estimated by echocardiography in 251 childhood acute lymphoblastic leukemia (cALL) patients. Association analyses revealed a modulating effect of two variants: A-1629 T in ABCC5, an ATP-binding cassette transporter, and G894T in the NOS3 endothelial nitric oxide synthase gene. Individuals with the ABCC5 TT-1629 genotype had an average of 8-12% reduction of ejection (EF) and shortening fractions (SF; EF: P<0.0001, and SF: P=0.001, respectively). A protective effect of the NOS3 TT894 genotype on EF was seen in high-risk patients (P=0.02), especially in those who did not receive dexrazoxane (P=0.002). Analysis of an additional cohort of 44 cALL patients replicated the ABCC5 association but was underpowered for NOS3. In summary, we identified two biomarkers that may contribute to cALL anthracycline CT risk stratification.

References

Sep 1, 1989·Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography·N B SchillerI Schnittger
Jul 1, 1996·Annals of Internal Medicine·K ShanJ B Young
Jul 13, 2000·The Journal of Biological Chemistry·G JedlitschkyD Keppler
Jul 27, 2000·Journal of Cellular Physiology·J A CarvajalC P Weiner
Dec 18, 2001·International Journal of Cancer. Journal International Du Cancer·M YoshidaM Fukuoka
Oct 16, 2002·Heart Failure Reviews·Imran N MungrueDuncan J Stewart
Apr 1, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Stefano FogliMaria Cristina Breschi
Jul 13, 2004·The New England Journal of Medicine·Leontine C M Kremer, Huib N Caron
Jul 13, 2004·The New England Journal of Medicine·Steven E LipshultzStephen E Sallan
Apr 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven E LipshultzSteven D Colan
Mar 19, 2008·Heart·Steven E LipshultzRebecca E Scully
Mar 25, 2009·Naunyn-Schmiedeberg's Archives of Pharmacology·Shiwei DengLeszek Wojnowski
Mar 23, 2010·Current Drug Metabolism·Suman LalBalram Chowbay
Nov 5, 2010·Pharmacogenetics and Genomics·Caroline F ThornRuss B Altman
Sep 9, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henk VisscherUNKNOWN Canadian Pharmacogenomics Network for Drug Safety Consortium
Sep 21, 2011·Cell Biology International·Agnes F SemseiGabor T Kovacs
Mar 12, 2013·Journal of Cardiovascular Pharmacology·Anne-Katrin PolanskiCarsten Wunderlich
Apr 25, 2013·Journal of Pediatric Hematology/oncology·Sophie MarcouxMaja Krajinovic
Jan 29, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Xuexia WangSmita Bhatia
Apr 10, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Salim KhiatiYves Pommier
Jun 8, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mohsen Ben TanfousMaja Krajinovic

❮ Previous
Next ❯

Citations

Jan 15, 2016·Cancer·Steven E LipshultzUNKNOWN Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium
Jun 5, 2016·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Hong-Qi LiLi-Qun Hu
May 28, 2016·Current Treatment Options in Cardiovascular Medicine·Jyothsna Akam-VenkataSteven E Lipshultz
Sep 7, 2016·British Journal of Clinical Pharmacology·Kelley K HutchinsSteven E Lipshultz
Sep 10, 2016·Pharmacology & Therapeutics·Tarek MagdyPaul W Burridge
Jul 7, 2017·Expert Opinion on Drug Metabolism & Toxicology·Neha BansalSteven E Lipshultz
Aug 21, 2018·Current Opinion in Pediatrics·Neha BansalSteven E Lipshultz
Mar 21, 2018·Circulation. Genomic and Precision Medicine·Marijke LinschotenFolkert W Asselbergs
Nov 22, 2018·Clinical Pharmacology and Therapeutics·Anne TripaydonisDavid A Elliott
Jan 29, 2019·Cardiovascular Research·Emily A PinheiroPaul W Burridge
Jul 1, 2020·Human Molecular Genetics·Jennifer K HockingsFeixiong Cheng
Mar 21, 2017·Current Hematologic Malignancy Reports·Rochelle R Maxwell, Peter D Cole
May 20, 2016·British Journal of Clinical Pharmacology·Folefac AminkengUNKNOWN CPNDS Clinical Practice Recommendations Group
Sep 16, 2017·Breast Cancer Research and Treatment·Sara Ruiz-PintoAnna González-Neira
Dec 30, 2017·Pediatric Blood & Cancer·Rachel ConyersDavid Elliott
Sep 20, 2017·Pharmacoepidemiology and Drug Safety·Ann W McMahonPhilip H Sheridan
Jul 13, 2018·Frontiers in Cardiovascular Medicine·Oday F SalmanMarwan M Refaat
Aug 11, 2020·Expert Opinion on Drug Metabolism & Toxicology·Kateryna PetrykeyMaja Krajinovic
Sep 21, 2018·American Society of Clinical Oncology Educational Book·Saro Armenian, Smita Bhatia
Aug 5, 2020·Expert Opinion on Drug Metabolism & Toxicology·Cezar Kayzuka Cotta FilhoRiccardo Lacchini
Oct 17, 2017·Annual Review of Medicine·Maria Monica Gramatges, Smita Bhatia
Mar 25, 2020·Human Genetics·Qingyang XiaoVolker M Lauschke
Jan 16, 2021·Pharmacogenomics·Tarek Magdy, Paul W Burridge
Jan 22, 2021·Arteriosclerosis, Thrombosis, and Vascular Biology·Chi Keung Lam, Joseph C Wu
Oct 29, 2020·Oxidative Medicine and Cellular Longevity·Xinyu YangHongcai Shang
Aug 17, 2020·Current Opinion in Pediatrics·Erika N ScottColin J D Ross
Apr 20, 2021·Clinical Genetics·Amy M BerkmanAndrew P Landstrom
Mar 7, 2021·Pharmacogenetics and Genomics·Juan Eduardo Megías-VericatPau Montesinos
Sep 26, 2021·Current Opinion in Pediatrics·Kristie N RamosKenneth S Ramos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.